Instruction for use: Bacteriophagum Coli fluidum

Dosage form: Solution for topical and oral administration

Active substance: Bacteriophagum coli

ATX

V03A Therapeutic preparations other

Pharmacological group:

Vaccines, serums, phages and toxoids

The nosological classification (ICD-10)

A04.1 Enterotoxigenic infection caused by Escherichia coli: Coli infection

A04.2 Enteroinvasive infection caused by Escherichia coli: Coli infection

A04.3 enterohemorrhagic infection caused by Escherichia coli: Coli infection

A04.4 Other intestinal infections caused by Escherichia coli: Coli infection

B96.2 Escherichia coli [E. coli]: Escherichia coli

L08.9 Local infection of skin and subcutaneous tissue, unspecified: Soft tissue abscess; Bacterial or fungal infection of the skin; Bacterial skin infections; Bacterial infections of soft tissues; Bacterial skin infections; Bacterial skin lesions; Viral infection of the skin; Viral skin infections; Inflammation of cellulose; Inflammation of the skin at the injection site; Inflammatory skin diseases; Pustular skin diseases; Purulent-inflammatory disease of skin and soft tissues; Purulent-inflammatory skin diseases; Purulent-inflammatory diseases of the skin and its appendages; Purulent-inflammatory diseases of soft tissues; Purulent skin infections; Purulent infections of soft tissues; Skin Infections; Infections of the skin and skin structures; Infectious lesions of the skin; Infectious diseases of the skin; Skin Infection; Infection of the skin and its appendages; Infection of the skin and subcutaneous structures; Infection of the skin and mucous membranes; Infection of the skin; Dermal bacterial infections; Uncomplicated skin infections; Uncomplicated soft tissue infections; Surface erosion of the skin with secondary infection; Umbilical infection; Mixed skin infections; Specific infectious processes in the skin; Superinfection of the skin; Necrotizing subcutaneous infections

N76 Other inflammatory diseases of the vagina and vulva: Vulvovaginitis atrophic; Vulvovaginitis bacterial; Vulvovaginitis estrogen-deficient; Bacterial vaginosis; Vaginitis; Vaginitis bacterial; Inflammatory diseases of the vagina and vulva; Inflammatory diseases of female genitalia; Inflammatory diseases of female genital organs; Vulvit; Vulvovaginitis; Vulvovaginitis; Gardnerella; Fungal vulvovaginitis in girls and virgins; Infection of the vagina; Infection of the genitals; Colpitis; Violation of purity of the vaginal secretion; Nonspecific cervicovaginitis; Nonspecific vulvitis; Nonspecific vulvovaginitis; Nonspecific colpitis; Recurrent nonspecific bacterial vaginosis; Senylic coverings; Mixed Colpus; Chronic vaginitis; Vulvovaginal infections; Bacterial vaginitis; Bacterial vaginosis; Bacterial vaginitis; Mixed vaginal infections

Composition and release form

Phagolysate filtrate of Escherichia coli secreted in purulent infections; Preservative quinazole (0.01 mg / ml). Liquid in bottles of 100 and 20 ml.

Pharmachologic effect

Mode of action - Immunostimulating.

Causes lysis of E. coli.

Indications Bacteriophagum Coli fluidum

Infections of the skin and internal organs caused by E. coli bacteria.

Contraindications

No.

Side effects

Not identified.

Dosing and Administration

Locally in the form of irrigation, lotion and tamponing (depending on the size of the affected area - 5-100 ml, intracavitary (30-100 ml) with the capillary drainage, through which for a few days the bacteriophage is re-introduced, with cystitis injected into the bladder through Catheter .When purulent pleurisy, bursitis or arthritis is injected into the cavity (after pumping pus) - 50-200 ml and more 3-4 times a day.

Precautionary measures

Drugs are not suitable for use in opacities and the presence of flakes.

Storage conditions of the drug Bacteriophagum Coli fluidum

In dry, the dark place at a temperature of 2-10 ° C.

Keep out of the reach of children.

Shelf life of the drug Bacteriophagum Coli fluidum

2 years.

Do not use after the expiry date printed on the package.